Free Trial

MBX Biosciences, Inc.'s Lock-Up Period Set To End on March 12th (NYSE:MBX)

MBX Biosciences logo with Medical background
Remove Ads

MBX Biosciences' (NYSE:MBX - Get Free Report) lock-up period will expire on Wednesday, March 12th. MBX Biosciences had issued 10,200,000 shares in its IPO on September 13th. The total size of the offering was $163,200,000 based on an initial share price of $16.00. After the expiration of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

MBX Biosciences Price Performance

Shares of MBX traded down $0.37 during trading hours on Friday, hitting $9.89. The stock had a trading volume of 138,702 shares, compared to its average volume of 226,513. The business's 50 day moving average is $11.83. MBX Biosciences has a 1-year low of $8.63 and a 1-year high of $27.50.

Insider Activity

In other news, CEO P. Kent Hawryluk bought 50,000 shares of MBX Biosciences stock in a transaction dated Tuesday, February 4th. The stock was bought at an average cost of $10.69 per share, for a total transaction of $534,500.00. Following the purchase, the chief executive officer now directly owns 448,277 shares in the company, valued at approximately $4,792,081.13. This represents a 12.55 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Carl L. Gordon purchased 47,502 shares of the company's stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average cost of $9.87 per share, for a total transaction of $468,844.74. Following the transaction, the director now owns 3,205,930 shares in the company, valued at $31,642,529.10. This represents a 1.50 % increase in their position. The disclosure for this purchase can be found here. Insiders bought a total of 240,672 shares of company stock worth $2,555,308 in the last three months.

Remove Ads

Hedge Funds Weigh In On MBX Biosciences

Several large investors have recently added to or reduced their stakes in MBX. BNP Paribas Financial Markets bought a new position in MBX Biosciences in the 4th quarter valued at about $27,000. Virtus ETF Advisers LLC bought a new position in MBX Biosciences in the 4th quarter valued at about $64,000. Deutsche Bank AG bought a new position in MBX Biosciences in the 4th quarter valued at about $80,000. Corebridge Financial Inc. bought a new position in MBX Biosciences in the 4th quarter valued at about $103,000. Finally, Wells Fargo & Company MN bought a new position in MBX Biosciences in the 4th quarter valued at about $108,000.

About MBX Biosciences

(Get Free Report)

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.

Read More

Should You Invest $1,000 in MBX Biosciences Right Now?

Before you consider MBX Biosciences, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MBX Biosciences wasn't on the list.

While MBX Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.

Get This Free Report
Like this article? Share it with a colleague.
Remove Ads

Featured Articles and Offers

Recent Videos

Institutions Are Dumping These 3 Stocks—Should You?
Will Tesla’s Robot Future Save Its Falling Stock?
NVIDIA’s Dip Is a Gift—Here’s Why It Won’t Last

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines

Remove Ads